Micromet Report Positive Results In Early Stage Leukemia Drug Trial

Officials with Micromet are reporting positive results from a clinical trial of an experimental drug to treat people with acute lymphoblastic leukemia.

This type of cancer is a blood cancer, that attacks white blood cells in the body but the drug, blinatumomab, appeared to slow down the progress of the cancer.

The goal for the drug going into the study was for it to induce an immune response within 4 rounds of treatment, which it ended up doing for the majority of patients studied.

The next phase of drug development is to carry out a larger clinical trial in order to provide more positive evidence towards the overall effectiveness of the drug.

Data from this initial drug trial was presented at the 14th Congress of the European Hematology Association in Berlin.

“We are excited about the significant activity of blinatumomab in ALL and the favorable safety profile observed in this study. These results are particularly important for these patients who are in a disease stage with extremely poor prognosis and for which we lack treatment options except for patients eligible for allogenic stem cell transplantations,” said Dr. Ralf Bargou, principal investigator of the trial, in a statement.